Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.

Summary

In a multinational phase 3, open-label trial (n=509), tarlatamab significantly improved overall survival versus physician’s-choice chemotherapy in relapsed SCLC after platinum (median 13.6 vs 8.3 months; HR 0.60), with lower rates of grade ≥3 adverse events and fewer discontinuations. Progression-free survival and patient-reported respiratory symptoms (dyspnea, cough) also favored tarlatamab.

Key Findings

• Median overall survival improved to 13.6 months with tarlatamab vs 8.3 months with chemotherapy (HR 0.60, P<0.001).
• Lower incidence of grade ≥3 adverse events (54% vs 80%) and fewer treatment discontinuations (5% vs 12%) with tarlatamab.
• Progression-free survival and patient-reported dyspnea and cough also favored tarlatamab.

Clinical Implications

Tarlatamab should be considered a preferred second-line option after platinum-based chemotherapy for SCLC, with improved OS and tolerability over current chemotherapy standards. Clinicians should monitor for immune-related and neurologic toxicities consistent with T-cell engagers.

Limitations

• Open-label design may introduce assessment bias despite hard endpoints
• Interim analysis; longer follow-up needed for durability and late toxicity
• Generalizability across global practice settings and prior lines may vary

Future Directions

Define biomarker subsets (e.g., DLL3 expression, TME features) predicting response, optimize sequencing with lurbinectedin/IO, and assess real-world effectiveness and quality-of-life outcomes.